Medline to Acquire ASID BONZ
Medline International B.V., a leading manufacturer and distributor of healthcare supplies in Europe, and Medi-Globe Group, headquartered in Germany, announced today that Medline has entered into a definitive agreement to acquire 100% of shares of ASID BONZ GmbH from Medi-Globe Group.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220405005920/en/
Medi-Globe Group CEO Martin Lehner: "The sale increases Medi-Globe’s focus on the core business - the development and marketing of innovative single-use products for minimally invasive diagnostic and therapeutic procedures”. (Photo: Medi-Globe Group)
ASID BONZ is a leading supplier to hospitals in Germany, offering high-quality surgery, anesthesia, ward-supply and urology products. ASID BONZ was founded in 1811 and is known worldwide for the development of the first anesthetic ether. In 2021, ASID BONZ recorded over 30mio Euros in revenues and served over 1.100 hospitals in Germany.
With similar business models and reputations for outstanding customer service, the two companies have an excellent strategic fit. Looking forward, Medline will make the ASID BONZ brand available outside of Germany to its broad European customer base. Within Germany, the ASID BONZ sales force will have access to Medline products to strengthen their partnership with customers.
“We are excited to increase our product offering and work with this award-winning organization with a renowned customer focus”, said Tripp Amdur, Medline Europe Group President. “Medline is a relatively new player in urology and anesthesia. This acquisition grows our presence in these areas of the hospital. ASID BONZ’s employees, products and service have a long-standing and trusted reputation and this combination will enable us to better meet the needs of our healthcare customers and become a more valued partner”.
Martin Lehner, CEO of Medi-Globe Group adds: “ASID BONZ is known for its unwavering commitment to its customers, providing high-quality medical products that are used to treat patients every day. We are sure that under the ownership of Medline, ASID BONZ will provide substantial avenues of growth in the future. The sale increases Medi-Globe’s focus on the core business - the development and marketing of innovative single-use products for minimally invasive diagnostic and therapeutic procedures”.
Transaction Details
We anticipate the investment will be completed in May 2022 once merger control approval has been obtained and other closing conditions have been fulfilled.
About Medline
With 27,000 employees worldwide and an especially strong presence in North America and Europe, Medline is a leading global healthcare company that manufactures and distributes quality medical and surgical supplies with superior value. Medline takes pride in serving its customers’ needs and improving healthcare around the globe, every day. Medline Europe was established in 2011. Since then, the company has expanded rapidly throughout the continent, serving customers in 27 European countries and with offices, manufacturing and distribution centers across the continent. Learn more about Medline at medline.eu
About Medi-Globe Group
The Medi-Globe Group is an innovative, fast-growing and internationally oriented medical technology group in the fields of urology, gastroenterology and pneumology. The head office is in Achenmuehle in Chiemgau, Bavaria, around 70 kilometers south of Munich. Around 670 employees work for the Medi-Globe Group, which was founded in 1990, in Germany, France, the Czech Republic, China, Brazil, the Netherlands and Austria. Customers include university clinics, specialist clinics, special medical facilities and specialists in gastroenterology, urology and pneumology in around 120 countries worldwide. The managing directors are Martin Lehner (CEO), Christian Klein (COO), Dr. Nikolaus König (CFO) and Marc Jablonowski (CTIO). More information at www.medi-globe.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005920/en/
Contact information
Medi-Globe Group
Carola Zollmann
press@medi-globe.de
braun communications
Stefanie Braun
+49 171 2 888 214
sb@brauncommunications.de
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom